| Symbol | ALLR |
|---|---|
| Name | ALLARITY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 123 E TARPON AVE, TARPON SPRINGS, Florida, 34689, United States |
| Telephone | +1 401 - 426-4664 |
| Fax | — |
| — | |
| Website | https://www.allarity.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Additional info from NASDAQ: |
(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Enrollment Update for Association Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAllarity Therapeutics Presents Two AACR 2026 Posters HighlightingStenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Read moreAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
Read moreNew Form PRE 14A - Allarity Therapeutics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001213900-26-042600 <b>Size:</b> 11 MB
Read more(19% Negative) ALLARITY THERAPEUTICS, INC. (ALLR) Reports Q1 2026 Financial Results
Read moreAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Read moreAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
Read more(19% Negative) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Delay in note Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more(99% Neutral) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Business Combination
Read moreAllarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05571969 | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy… | Phase1 | Advanced Solid Tumors | Suspended | 2023-02-20 | 2025-12-01 | ClinicalTrials.gov |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by … | Phase2 | Metastatic Breast Cancer | Terminated | 2021-03-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT03877796 | Clinical Pre-screening Protocol for Ovarian Cancer | — | Ovarian Cancer | Recruiting | 2019-04-11 | 2026-12-01 | ClinicalTrials.gov |
| NCT03643107 | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Resp… | Phase2 | Metastatic Castration-Resistant Prostate Cancer Patients | Completed | 2018-10-17 | 2022-08-01 | ClinicalTrials.gov |
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-1… | Phase2 | Metastatic Breast Cancer | Completed | 2018-06-20 | 2024-08-01 | ClinicalTrials.gov |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Mu… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2017-06-13 | 2020-01-16 | ClinicalTrials.gov |
| NCT01861496 | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patient… | Phase1 | Phase 1: Advanced or Refractory Solid Tumours | Completed | 2013-04-01 | 2021-10-01 | ClinicalTrials.gov |